Skip to main content

Advertisement

SpringerLink
Log in

Differences in prognosis and efficacy of chemotherapy by p53 expression in triple-negative breast cancer

  • Clinical trial
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

Purpose

TP53 mutation is the most common mutation in breast cancer, and it is considered a target marker of triple-negative breast cancer (TNBC). We investigated whether expression of p53 detected by immunochemical staining predicts the chemotherapy response of TNBC.

Methods

A total of 11,393 TNBC patients who had between stage I and stage III enrolled in the Korean Breast Cancer Society Registry database from January 1, 2000 to December 31, 2015. There were 6,331 ‘p53-positive (+) TNBC’ patients and 5062 ‘p53-negative (−) TNBC’ patients.

Results

In univariate analysis, p53(+) TNBC had a worse prognosis than p53(−) TNBC in patients not receiving chemotherapy (P = 0.003). However, there was no difference in prognosis between p53(+) TNBC and p53(−) TNBC for patients receiving chemotherapy. In multivariate analysis adjusted for age and stage, the risk of p53(+) TNBC was 1.84 times higher than that of p53(−) TNBC in the non-chemotherapy group. However, there was no difference between p53(+) TNBC and p53(−) TNBC in patients receiving chemotherapy. In p53(+) TNBC, the risk was 0.6-fold lower when chemotherapy was administered than when chemotherapy was not administered. However, in p53(−) TNBC, there was no risk reduction effect by chemotherapy.

Conclusion

The prognosis of p53(+) TNBC has worse than p53(−) TNBC, but the risk for survival was significantly reduced with chemotherapy. It suggests that p53(+) TNBC would be more sensitive to chemotherapy than p53(−) TNBC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO (2007) Prognostic markers in triple-negative breast cancer. Cancer 109(1):25–32

    Article  CAS  Google Scholar 

  2. Haffty BG, Yang Q, Reiss M, Kearney T, Higgins SA, Weidhaas J, Harris L, Hait W, Toppmeyer D (2006) Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 24(36):5652–5657

    Article  Google Scholar 

  3. Brenton JD, Carey LA, Ahmed AA, Caldas C (2005) Molecular classification and molecular forecasting of breast cancer: ready for clinical application? J Clin Oncol 23(29):7350–7360

    Article  CAS  Google Scholar 

  4. Network CGA (2012) Comprehensive molecular portraits of human breast tumours. Nature 490(7418):61–70

    Article  Google Scholar 

  5. Ahn SH, Yoo KY (2006) Chronological changes of clinical characteristics in 31,115 new breast cancer patients among Koreans during 1996–2004. Breast Cancer Res Treat 99(2):209–214

    Article  Google Scholar 

  6. Ahn SH, Son BH, Kim SW, Kim SI, Jeong J, Ko SS, Han W (2007) Poor outcome of hormone receptor-positive breast cancer at very young age is due to tamoxifen resistance: nationwide survival data in Korea—a report from the Korean Breast Cancer Society. J Clin Oncol 25(17):2360–2368

    Article  Google Scholar 

  7. Synnott NC, Bauer MR, Madden S, Murray A, Klinger R, O’Donovan N, O’Connor D, Gallagher WM, Crown J, Fersht AR et al (2018) Mutant p53 as a therapeutic target for the treatment of triple-negative breast cancer: preclinical investigation with the anti-p53 drug, PK11007. Cancer Lett 414:99–106

    Article  CAS  Google Scholar 

  8. Duffy MJ, Synnott NC, Crown J (2018) Mutant p53 in breast cancer: potential as a therapeutic target and biomarker. Breast Cancer Res Treat 170(2):213–219

    Article  CAS  Google Scholar 

  9. Blagosklonny MV (1997) Loss of function and p53 protein stabilization. Oncogene 15(16):1889–1893

    Article  CAS  Google Scholar 

  10. Thor AD, Moore DH, Edgerton II, Kawasaki SM, Reihsaus ES, Lynch E, Marcus HT, Schwartz JN, Chen L, Mayall LC (1992) BH et al: Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. J Natl Cancer Inst 84(11):845–855

    Article  CAS  Google Scholar 

  11. Brosh R, Rotter V (2009) When mutants gain new powers: news from the mutant p53 field. Nat Rev Cancer 9(10):701–713

    Article  CAS  Google Scholar 

  12. Petitjean A, Achatz MI, Borresen-Dale AL, Hainaut P, Olivier M (2007) TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene 26(15):2157–2165

    Article  CAS  Google Scholar 

  13. Joerger AC, Fersht AR (2016) The p53 pathway: origins, inactivation in cancer, and emerging therapeutic approaches. Annu Rev Biochem 85(1):375–404

    Article  CAS  Google Scholar 

  14. Abdel-Fattah R, Challen C, Griffiths TR, Robinson MC, Neal DE, Lunec J (1998) Alterations of TP53 in microdissected transitional cell carcinoma of the human urinary bladder: high frequency of TP53 accumulation in the absence of detected mutations is associated with poor prognosis. Br J Cancer 77(12):2230–2238

    Article  CAS  Google Scholar 

  15. George B, Datar RH, Wu L, Cai J, Patten N, Beil SJ, Groshen S, Stein J, Skinner D, Jones PA et al (2007) p53 gene and protein status: the role of p53 alterations in predicting outcome in patients with bladder cancer. J Clin Oncol 25(34):5352–5358

    Article  CAS  Google Scholar 

  16. Lipponen P, Ji H, Aaltomaa S, Syrjanen S, Syrjanen K (1993) p53 protein expression in breast cancer as related to histopathological characteristics and prognosis. Int J Cancer 55(1):51–56

    Article  CAS  Google Scholar 

  17. Olivier M, Langerod A, Carrieri P, Bergh J, Klaar S, Eyfjord J, Theillet C, Rodriguez C, Lidereau R, Bieche I et al (2006) The clinical value of somatic TP53 gene mutations in 1794 patients with breast cancer. Clin Cancer Res 12(4):1157–1167

    Article  CAS  Google Scholar 

  18. Coates AS, Millar EK, O’Toole SA, Molloy TJ, Viale G, Goldhirsch A, Regan MM, Gelber RD, Sun Z, Castiglione-Gertsch M et al (2012) Prognostic interaction between expression of p53 and estrogen receptor in patients with node-negative breast cancer: results from IBCSG Trials VIII and IX. Breast Cancer Res 14(6):R143

    Article  CAS  Google Scholar 

  19. Lara JF, Thor AD, Dressler LG, Broadwater G, Bleiweiss IJ, Edgerton S, Cowan D, Goldstein LJ, Martino S, Ingle JN et al (2011) p53 Expression in node-positive breast cancer patients: results from the cancer and leukemia group B 9344 Trial (159905). Clin Cancer Res 17(15):5170–5178

    Article  CAS  Google Scholar 

  20. Fernandez-Cuesta L, Oakman C, Falagan-Lotsch P, Smoth KS, Quinaux E, Buyse M, Dolci MS, Azambuja ED, Hainaut P, Dell’orto P et al (2012) Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial. Breast Cancer Res 14(3):R70

    Article  CAS  Google Scholar 

  21. Silwal-Pandit L, Vollan HK, Chin SF, Rueda OM, McKinney S, Osako T, Quigley DA, Kristensen VN, Aparicio S, Borresen-Dale AL et al (2014) TP53 mutation spectrum in breast cancer is subtype specific and has distinct prognostic relevance. Clin Cancer Res 20(13):3569–3580

    Article  CAS  Google Scholar 

  22. Bertheau P, Turpin E, Rickman DS, Espie M, de Reynies A, Feugeas JP, Plassa LF, Soliman H, Varna M, de Roquancourt A et al (2007) Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen. PLoS Med 4(3):e90

    Article  Google Scholar 

  23. Bertheau P, Plassa F, Espie M, Turpin E, de Roquancourt A, Marty M, Lerebours F, Beuzard Y, Janin A, de The H (2002) Effect of mutated TP53 on response of advanced breast cancers to high-dose chemotherapy. Lancet 360(9336):852–854

    Article  CAS  Google Scholar 

  24. Lehmann-Che J, Andre F, Desmedt C, Mazouni C, Giacchetti S, Turpin E, Espie M, Plassa LF, Marty M, Bertheau P et al (2010) Cyclophosphamide dose intensification may circumvent anthracycline resistance of p53 mutant breast cancers. The Oncologist 15(3):246–252

    Article  CAS  Google Scholar 

  25. Silver DP, Richardson AL, Eklund AC, Wang ZC, Szallasi Z, Li Q, Juul N, Leong C-O, Calogrias D, Buraimoh A et al (2010) Efficacy of neoadjuvant cisplatin in triple-negative breast cancer. J Clin Oncol 28(7):1145–1153

    Article  CAS  Google Scholar 

  26. Varna M, Lehmann-Che J, Turpin E, Marangoni E, El-Bouchtaoui M, Jeanne M, Grigoriu C, Ratajczak P, Leboeuf C, Plassa LF et al (2009) p53 dependent cell-cycle arrest triggered by chemotherapy in xenografted breast tumors. Int J Cancer 124(4):991–997

    Article  CAS  Google Scholar 

  27. Jackson JG, Pant V, Li Q, Chang LL, Quintas-Cardama A, Garza D, Tavana O, Yang P, Manshouri T, Li Y et al (2012) p53-mediated senescence impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer. Cancer Cell 21(6):793–806

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This article was supported by the Korean Breast Cancer Society. This work was supported by the National Research Foundation of Korea (2017R1D1A1B03028103).

Author information

Authors and Affiliations

  1. Division of Breast and Endocrine Surgery, Department of Surgery, Korea University Anam Hospital, Korea University College of Medicine, 73 Inchon-ro, Seongbuk-gu, Seoul, 02841, Republic of Korea

    Soo Youn Bae, Hsien Wen Yang & Seung Pil Jung

  2. Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea

    Seok Jin Nam

  3. Department of Surgery, Ajou University School of Medicine, Gyeonggi-do, Republic of Korea

    Yongsik Jung

  4. Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea

    Sae Byul Lee

  5. Department of Surgery, Yonsei University College of Medicine, Seoul, Republic of Korea

    Byung-Woo Park

  6. Department of Surgery, Ewha Womans University Mokdong Hospital, Ewha Womans University College of Medicine, Seoul, Republic of Korea

    Woosung Lim

  7. Department of Surgery, Chonbuk National University Hospital, Chonbuk National University Medical School, Jeonju, Republic of Korea

    Sung Hoo Jung

Authors
  1. Soo Youn Bae
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Seok Jin Nam
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yongsik Jung
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sae Byul Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Byung-Woo Park
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Woosung Lim
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Sung Hoo Jung
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Hsien Wen Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Seung Pil Jung
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Soo Youn Bae or Seung Pil Jung.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.

Informed consent

For this type of study informed consent is not required.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bae, S.Y., Nam, S.J., Jung, Y. et al. Differences in prognosis and efficacy of chemotherapy by p53 expression in triple-negative breast cancer. Breast Cancer Res Treat 172, 437–444 (2018). https://doi.org/10.1007/s10549-018-4928-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-018-4928-2

Keywords

Search

Navigation